
|Articles|July 1, 2004
New Products & Services
Lexington, MA-Indevus Pharmaceuticals announced that trospium chloride (Sanctura) has been approved by the FDA for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5


















